{"doc_id": "si-2022-0040-reg-1", "parent_doc_id": "si-2022-0040", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "1. These Regulations may be cited as the European Union (Clinical Trials", "text_raw": "1. These Regulations may be cited as the European Union (Clinical Trials \n\non Medicinal Products for Human Use) Regulations 2022. \n\nCommencement", "text_norm": "1 regulation may cited european union (clinical trial medicinal product human use) regulation 2022 commencement", "start_char": 772, "end_char": 919, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-2", "parent_doc_id": "si-2022-0040", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "2. These Regulations shall come into operation on the 31st day of January", "text_raw": "2. These Regulations shall come into operation on the 31st day of January", "text_norm": "2 regulation shall come operation 31st day january", "start_char": 919, "end_char": 995, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-2022", "parent_doc_id": "si-2022-0040", "section_id": "reg-2022", "section_label": "Regulation 2022.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "Application", "text_raw": "2022. \n\nApplication", "text_norm": "2022 application", "start_char": 995, "end_char": 1017, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-3", "parent_doc_id": "si-2022-0040", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "3. (1) These Regulations apply to the authorisation and conduct of clinical", "text_raw": "3. (1) These Regulations apply to the authorisation and conduct of clinical \n\ntrials. \n\n(2) These Regulations shall not apply to non-interventional studies. \n\nInterpretation", "text_norm": "3 (1) regulation apply authorisation conduct clinical trial (2) regulation shall apply non-interventional study interpretation", "start_char": 1017, "end_char": 1193, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-4", "parent_doc_id": "si-2022-0040", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "4. (1) In these Regulations—", "text_raw": "4. (1) In these Regulations— \n\n“Advisory Committee for Human Medicines” means the committee established \nby section 9 of the Irish Medicines Board Act 1995 (No. 29 of 1995), as \namended; \n\n“Assessment Report” has the meaning assigned to it in Article 6 of the Clinical \nTrials Regulation; \n\n“Authority” means the Health Products Regulatory Authority established by \nsection 3 of the Irish Medicines Board Act 1995 (No. 29 of 1995), as amended; \n\n1 OJ L 158, 27.05.2014, p.1 \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 4th February, 2022. \n\n \n \n \n \n \n \n \n \n \n \n\f[40] 3 \n\n“Clinical Trials Regulation” means Regulation (EU) No. 536/2014 of the \nEuropean Parliament and of the Council of 16 April 2014 on clinical trials on \nmedicinal products for human use; \n\n“clinical study” has the same meaning as it has in the Clinical Trials \nRegulation; \n\n“clinical trial” has the same meaning as it has in the Clinical Trials Regulation; \n\n“Declaration of Helsinki” means the Declaration of Helsinki adopted by the \nGeneral Assembly of the World Medical Association in June 1964, and as \namended by the General Assembly of that Association from time to time; \n\n“Directive” means Directive 2001/20/EC of the European Parliament and of \nthe Council of 4 April 2001 on the approximation of the laws, regulations and \nadministrative provisions of the Member States relating to the implementation \nof good clinical practice in the conduct of clinical trials on medicinal products \nfor human use; \n\n“ethics committee” means a committee established under Part 3 of the \nEuropean Union (Clinical Trials on Medicinal Products for Human Use) \n(National Research Ethics Committees) Regulations 2022 (SI No. 41 of 2022) \nfor the purposes of the Clinical Trials Regulation; \n\n“EU database” means the database established under Article 81 of the Clinical \nTrials Regulation; \n\n“EU portal” means the electronic portal established under Article 80 of the \nClinical Trials Regulation; \n\n“General Data Protection Regulation” means Regulation (EU) 2016/679 of the \nEuropean Parliament and of the Council of 27 April 2016 on the protection of \nnatural persons with regard to the processing of personal data and on the free \nmovement of such data, and repealing Directive 95/46/EC; \n\n“incapacitated subject” has the same meaning as it has in the Clinical Trials \nRegulation; \n\n“investigator” for the purposes of Article 49 of the Clinical Trials Regulation \nand these Regulations means – \n\n(a) \n\n(b) \n\n(c) \n\na medical practitioner within the meaning of section 2 of the \nMedical Practitioners Act 2007 (No. 25 of 2007), \n\na visiting EEA practitioner within the meaning of section 2 of \nthe Medical Practitioners Act 2007, or \n\na registered dentist within the meaning of section 2 of the \nDentists Act 1985 (No. 9 of 1985); \n\n“Joint Controllership Arrangement” means the arrangement agreed by the \nEuropean Commission, European Medicines Agency, Member States, sponsors \nand marketing authorisation applicants or holders for the purpose of processing \npersonal data captured in the EU portal; \n\n“legally designated representative”, for the purposes of these Regulations and \nthe Clinical Trials Regulation only, means— \n\n \n\f4 [40] \n\n(a) \n\nin relation to an incapacitated subject who is, or is being \nconsidered as, a subject for a clinical trial— \n\n(i) \n\na person, other than a person connected with the conduct \nof the trial, who by virtue of his or her family or other \npersonal relationship with the individual— \n\n(aa) can provide the best interpretation of the will and \npreferences of the individual based on their \nknowledge of the individual, \n\n(bb) is available and willing to act for that purpose, or \n\n(ii) \n\nif there is no such person, the medical practitioner \nprimarily responsible for the medical treatment provided \nto the individual where he or she— \n\n(aa) can provide the best interpretation of the will and \npreferences of the individual based on their \nknowledge of the individual, \n\n(bb) is not involved in the conduct of the trial, \n\n(cc) \n\nis of the view that participation in the trial will not \nprejudice the health and wellbeing of the individual, \nand \n\n(dd) is available and willing to act for that purpose, and \n\n(b) \n\nin relation to a minor who is, or is being considered as, a subject \nfor a clinical trial, a guardian within the meaning of the \nGuardianship of Infants Act 1964 (No. 7 of 1964); \n\n“legal representative” has the meaning assigned to it by Article 74 of the \nClinical Trials Regulation; \n\n“marketing authorisation” means an authorisation which is for the time being \nin force and which has been granted by the Authority under the Medicinal \nProducts (Control of Placing on the Market) Regulations 2007 or by the \nCommission under Regulation (EC) No. 726/2004 and includes a marketing \nauthorisation issued by the competent authority of an EEA State, other than the \nState, in accordance with Directive 2001/83/EC2; \n\n“manufacturer’s authorisation” means an authorisation for the manufacture or \nimport of investigational medicinal products or auxiliary medicinal products, \nwhich is for the time being in force and which has been granted by the \nAuthority; \n\n“Minister” means the Minister for Health; \n\n“minor” means a person under the age of 16 years; \n\n“National Office” has the meaning assigned to it by Regulation 5 of the \nEuropean Union Clinical Trials on Medicinal Products for Human Use) \n(National Research Ethics Committees) Regulations 2022 (S.I. No. 41 of \n2022); \n\n2 OJ No. L 311, 28.11.2001, p. 67. \n\n \n \n\f[40] 5 \n\n“National Research Ethics Committee” has the meaning assigned to it by \nRegulation 13 of the European Union (Clinical Trials on Medicinal Products \nfor Human Use) (National Research Ethics Committees) Regulations 2022 (S.I. \nNo. 41 of 2022); \n\n“nominated ethics committee” means the National Research Ethics Committee \nnominated by the National Office to assess and provide an opinion on a \nspecific clinical trial application, or substantial modification to a clinical trial \ngranted authorisation, pursuant to the Clinical Trials Regulation; \n\n“non-commercial sponsor” means a sponsor which has no commercial or \nfinancial interest in the outcome of the clinical trial; \n\n“non-commercial clinical trial\" means a clinical trial conducted by a noncommercial sponsor which fulfils the following characteristics: \n\n(a) \n\n(b) \n\nthe ownership of the investigation data belongs to the noncommercial sponsor from the inception of the clinical trial, and \n\nthe design, conduct, recruitment, recording of data and reporting \nof the results of the investigation remains under the control of \nthe non-commercial sponsor; \n\n“registered nurse” means a person registered in the Register of Nurses and \nMidwives established under section 46(1)(a) of the Nurses and Midwives Act \n2011 (No. 41 of 2011); \n\n“registered pharmacist” means a person registered in the Register of \nPharmacists established under section 13(1) of the Pharmacy Act 2007 (No. 20 \nof 2007); \n\n“Regulation (EC) No 726/2004” means regulations of the European Parliament \nand of the Council of 31 March 2004 laying down Community procedures for \nthe authorisation and supervision of medicinal products for human and \nveterinary use and establishing a European Medicines Agency; \n\n“Regulation (EU) 2017/556” means Commission Implementing Regulation \n(EU) 2017/556 of 24 March 2017 on the detailed arrangements for good \nclinical practice inspection procedures pursuant to the Clinical Trials \nRegulation; \n\n“subject” has the same meaning as it has in the Clinical Trials Regulation; \n\n“trial site” means a hospital, clinic, nursing home, health centre, surgery or \nother establishment or facility at or from which a clinical trial, or any part of \nsuch a trial, is conducted. \n\n(2) A word or expression which is used in these Regulations and which is \n\nalso used in the Clinical Trials Regulation has, unless the context otherwise \nrequires, the same meaning in these Regulations as it has in the Clinical Trials \nRegulation. \n\nRoles of Authority, National Office and Nominated Ethics Committee", "text_norm": "4 (1) regulations-- advisory committee human medicine mean committee established section 9 irish medicine board act 1995 (no 29 1995) amended assessment report meaning assigned article 6 clinical trial regulation authority mean health product regulatory authority established section 3 irish medicine board act 1995 (no 29 1995) amended 1 oj l 158 27.05.2014 p.1 notice making statutory instrument published iris oifigiuil 4th february 2022 40 3 clinical trial regulation mean regulation (eu) no 536 2014 european parliament council 16 april 2014 clinical trial medicinal product human use clinical study meaning clinical trial regulation clinical trial meaning clinical trial regulation declaration helsinki mean declaration helsinki adopted general assembly world medical association june 1964 amended general assembly association time time directive mean directive 2001 20 ec european parliament council 4 april 2001 approximation law regulation administrative provision member state relating implementation good clinical practice conduct clinical trial medicinal product human use ethic committee mean committee established part 3 european union (clinical trial medicinal product human use) (national research ethic committees) regulation 2022 (si no 41 2022) purpose clinical trial regulation eu database mean database established article 81 clinical trial regulation eu portal mean electronic portal established article 80 clinical trial regulation general data protection regulation mean regulation (eu) 2016 679 european parliament council 27 april 2016 protection natural person regard processing personal data free movement data repealing directive 95 46 ec incapacitated subject meaning clinical trial regulation investigator purpose article 49 clinical trial regulation regulation mean - (a) (b) (c) medical practitioner within meaning section 2 medical practitioner act 2007 (no 25 2007) visiting eea practitioner within meaning section 2 medical practitioner act 2007 registered dentist within meaning section 2 dentist act 1985 (no 9 1985) joint controllership arrangement mean arrangement agreed european commission european medicine agency member state sponsor marketing authorisation applicant holder purpose processing personal data captured eu portal legally designated representative purpose regulation clinical trial regulation means-- 4 40 (a) relation incapacitated subject considered subject clinical trial-- (i) person person connected conduct trial virtue family personal relationship individual-- (aa) provide best interpretation preference individual based knowledge individual (bb) available willing act purpose (ii) person medical practitioner primarily responsible medical treatment provided individual she-- (aa) provide best interpretation preference individual based knowledge individual (bb) involved conduct trial (cc) view participation trial prejudice health wellbeing individual (dd) available willing act purpose (b) relation minor considered subject clinical trial guardian within meaning guardianship infant act 1964 (no 7 1964) legal representative meaning assigned article 74 clinical trial regulation marketing authorisation mean authorisation time force granted authority medicinal product (control placing market) regulation 2007 commission regulation (ec) no 726 2004 includes marketing authorisation issued competent authority eea state state accordance directive 2001 83 ec2 manufacturer authorisation mean authorisation manufacture import investigational medicinal product auxiliary medicinal product time force granted authority minister mean minister health minor mean person age 16 year national office meaning assigned regulation 5 european union clinical trial medicinal product human use) (national research ethic committees) regulation 2022 (s.i no 41 2022) 2 oj no l 311 28.11.2001 p 67 40 5 national research ethic committee meaning assigned regulation 13 european union (clinical trial medicinal product human use) (national research ethic committees) regulation 2022 (s.i no 41 2022) nominated ethic committee mean national research ethic committee nominated national office ass provide opinion specific clinical trial application substantial modification clinical trial granted authorisation pursuant clinical trial regulation non-commercial sponsor mean sponsor commercial financial interest outcome clinical trial non-commercial clinical trial mean clinical trial conducted noncommercial sponsor fulfils following characteristic (a) (b) ownership investigation data belongs noncommercial sponsor inception clinical trial design conduct recruitment recording data reporting result investigation remains control non-commercial sponsor registered nurse mean person registered register nurse midwife established section 46(1)(a) nurse midwife act 2011 (no 41 2011) registered pharmacist mean person registered register pharmacist established section 13(1) pharmacy act 2007 (no 20 2007) regulation (ec) 726 2004 mean regulation european parliament council 31 march 2004 laying community procedure authorisation supervision medicinal product human veterinary use establishing european medicine agency regulation (eu) 2017 556 mean commission implementing regulation (eu) 2017 556 24 march 2017 detailed arrangement good clinical practice inspection procedure pursuant clinical trial regulation subject meaning clinical trial regulation trial site mean hospital clinic nursing home health centre surgery establishment facility clinical trial part trial conducted (2) word expression used regulation also used clinical trial regulation unless context otherwise requires meaning regulation clinical trial regulation role authority national office nominated ethic committee", "start_char": 1193, "end_char": 9329, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-5", "parent_doc_id": "si-2022-0040", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "5. (1) Subject to paragraph (2)—", "text_raw": "5. (1) Subject to paragraph (2)— \n\n \n \n\f6 [40] \n\n(a) \n\nthe role of Member State, pursuant to the Clinical Trials \nRegulation, shall be carried out by the Authority and the \nNational Office in conjunction with the Nominated Ethics \nCommittee, each of which— \n\n(i) may communicate information when carrying out their \n\nrespective functions under the Clinical Trials Regulation, \nand \n\n(ii) \n\nshall keep such communications confidential, \n\n(b) where the State is the reporting Member State under the Clinical \nTrials Regulation, the Authority and the National Office in \nconjunction with the Nominated Ethics Committee shall coordinate in the review of applications for the conduct of clinical \ntrials and applications for substantial modifications to clinical \ntrials granted authorisation, and perform the functions ascribed \nto the reporting Member State under the Clinical Trials \nRegulation, \n\n(c) where the State is a Member State concerned under the Clinical \nTrials Regulation, the Authority and the National Office in \nconjunction with the Nominated Ethics Committee shall perform \nthe functions ascribed to the Member State concerned under the \nClinical Trials Regulation, \n\n(d) where the State is an additional Member State concerned \n\npursuant to Article 14 of the Clinical Trials Regulation, the \nAuthority and the National Office in conjunction with the \nNominated Ethics Committee shall perform the functions \nascribed to additional Member States concerned under the \nClinical Trials Regulation, and \n\n(e) \n\nnotifications to the EU portal envisaged at Article 80 of the \nClinical Trials Regulation and submissions to the EU database \nenvisaged at Article 81 thereof shall be made by either the \nAuthority or the National Office, as appropriate. \n\n(f) \n\nthe Authority shall— \n\n(i) \n\nperform the scientific review referred to in Article 4 of the \nRegulation, \n\n(ii) validate the application dossier in accordance with \n\nChapters II and III of the Clinical Trials Regulation; \n\n(iii) be the national contact point for the purposes of Article 83 \n\nof the Clinical Trials Regulation, \n\n(iv) perform the inspections envisaged by Articles 63 and 78 \n\nof the Clinical Trials Regulation, \n\n(v) \n\ncollect the fees envisaged by Chapter XVI of the Clinical \nTrials Regulation, \n\n(vi) be responsible for the enforcement of these Regulations \nand the prosecution of any offences, thereunder \n\n \n\f[40] 7 \n\n(g) \n\nthe National Office, in conjunction with the Nominated Ethics \nCommittee, shall— \n\n(i) \n\nperform the ethical review referred to in Article 4 of the \nClinical Trials Regulation, \n\n(ii) validate the aspects covered by the Part II assessment, \n\npursuant to Chapters II and III of the Clinical Trials \nRegulation. \n\n(h) \n\n(i) \n\nthe National Office shall have the additional functions described \nin the European Union (Clinical Trials on Medicinal Products \nfor Human Use) (National Research Ethics Committees) \nRegulations 2022. \n\na National Research Ethics Committee shall have the additional \nfunctions described in the European Union (Clinical Trials on \nMedicinal Products for Human Use) (National Research Ethics \nCommittees) Regulations 2022. \n\n(2) The Minister may publish guidelines as to the appropriate division of \ntasks prescribed by the Clinical Trials Regulation, between the Authority, the \nNational Office and the nominated ethics committee, as appropriate. \n\nDETERMINATION OF ROLE AS REPORTING MEMBER STATE AND \nSCOPE OF APPLICATION \n\nPART 2", "text_norm": "5 (1) subject paragraph (2)-- 6 40 (a) role member state pursuant clinical trial regulation shall carried authority national office conjunction nominated ethic committee which-- (i) may communicate information carrying respective function clinical trial regulation (ii) shall keep communication confidential (b) state reporting member state clinical trial regulation authority national office conjunction nominated ethic committee shall coordinate review application conduct clinical trial application substantial modification clinical trial granted authorisation perform function ascribed reporting member state clinical trial regulation (c) state member state concerned clinical trial regulation authority national office conjunction nominated ethic committee shall perform function ascribed member state concerned clinical trial regulation (d) state additional member state concerned pursuant article 14 clinical trial regulation authority national office conjunction nominated ethic committee shall perform function ascribed additional member state concerned clinical trial regulation (e) notification eu portal envisaged article 80 clinical trial regulation submission eu database envisaged article 81 thereof shall made either authority national office appropriate (f) authority shall-- (i) perform scientific review referred article 4 regulation (ii) validate application dossier accordance chapter ii iii clinical trial regulation (iii) national contact point purpose article 83 clinical trial regulation (iv) perform inspection envisaged article 63 78 clinical trial regulation (v) collect fee envisaged chapter xvi clinical trial regulation (vi) responsible enforcement regulation prosecution offence thereunder 40 7 (g) national office conjunction nominated ethic committee shall-- (i) perform ethical review referred article 4 clinical trial regulation (ii) validate aspect covered part ii assessment pursuant chapter ii iii clinical trial regulation (h) (i) national office shall additional function described european union (clinical trial medicinal product human use) (national research ethic committees) regulation 2022 national research ethic committee shall additional function described european union (clinical trial medicinal product human use) (national research ethic committees) regulation 2022 (2) minister may publish guideline appropriate division task prescribed clinical trial regulation authority national office nominated ethic committee appropriate determination role reporting member state scope application part 2", "start_char": 9329, "end_char": 12795, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-6", "parent_doc_id": "si-2022-0040", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "6. (1) Subject to paragraph (2), the Authority shall determine whether the", "text_raw": "6. (1) Subject to paragraph (2), the Authority shall determine whether the \nState is willing to be the reporting Member State pursuant to Article 5(1) of the \nClinical Trials Regulation, or not, and shall notify any decision to all Member \nStates concerned through the EU Portal. \n\n(2) Before making its determination under paragraph (1), the Authority \n\nshall consult with the National Office. \n\nDetermination on scope of application", "text_norm": "6 (1) subject paragraph (2) authority shall determine whether state willing reporting member state pursuant article 5(1) clinical trial regulation shall notify decision member state concerned eu portal (2) making determination paragraph (1) authority shall consult national office determination scope application", "start_char": 12795, "end_char": 13232, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-7", "parent_doc_id": "si-2022-0040", "section_id": "reg-7", "section_label": "Regulation 7.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "7. The Authority shall assess whether the application for authorisation is", "text_raw": "7. The Authority shall assess whether the application for authorisation is \n\nwithin the scope of the Clinical Trials Regulation as envisaged by Article \n5(3)(a) thereof. \n\n \n \n \n \n \n \n\f8 [40] \n\nPART 3 \n\nCONDUCT OF CLINICAL TRIALS \n\nConduct of clinical trials within the State", "text_norm": "7 authority shall ass whether application authorisation within scope clinical trial regulation envisaged article 5(3)(a) thereof 8 40 part 3 conduct clinical trial conduct clinical trial within state", "start_char": 13232, "end_char": 13510, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-8", "parent_doc_id": "si-2022-0040", "section_id": "reg-8", "section_label": "Regulation 8.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "8. (1) Without prejudice to the Clinical Trials Regulation, in particular", "text_raw": "8. (1) Without prejudice to the Clinical Trials Regulation, in particular \n\nArticles 17 to 19, 21 to 23 and 47 thereof, a person shall not— \n\n(a) \n\nconduct a clinical trial, \n\n(b) perform the functions of the sponsor of a clinical trial (whether \nthat person is the sponsor or is acting under arrangements made \nwith that sponsor), or \n\n(c) \n\nperform the functions of the investigator of a clinical trial, \n\nin the State, otherwise than in accordance with paragraph (2). \n\n(2)The activities at paragraph 1(a) to (c) shall be conducted in accordance \n\nwith— \n\n(a) \n\n(b) \n\n(c) \n\n(d) \n\nthe Clinical Trials Regulation, \n\nthese Regulations, \n\nthe Declaration of Helsinki, \n\nthe authorisation to conduct that clinical trial as notified to the \nsponsor through the EU portal, \n\n(e) \n\nany clinical trial protocol relating to a particular clinical trial, \n\n(f) \n\nany particulars or documents, other than the clinical trial \nprotocol, accompanying a clinical trial application, as may be \nmodified from time to time in accordance with Articles 17 to 23 \nof the Clinical Trials Regulation, and \n\n(g) \n\nthe conditions and principles of good clinical practice. \n\nCompliance with obligations where the sponsor is not established in \nEuropean Union", "text_norm": "8 (1) without prejudice clinical trial regulation particular article 17 19 21 23 47 thereof person shall not-- (a) conduct clinical trial (b) perform function sponsor clinical trial (whether person sponsor acting arrangement made sponsor) (c) perform function investigator clinical trial state otherwise accordance paragraph (2) (2)the activity paragraph 1(a) (c) shall conducted accordance with-- (a) (b) (c) (d) clinical trial regulation regulation declaration helsinki authorisation conduct clinical trial notified sponsor eu portal (e) clinical trial protocol relating particular clinical trial (f) particular document clinical trial protocol accompanying clinical trial application may modified time time accordance article 17 23 clinical trial regulation (g) condition principle good clinical practice compliance obligation sponsor established european union", "start_char": 13510, "end_char": 14746, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-9", "parent_doc_id": "si-2022-0040", "section_id": "reg-9", "section_label": "Regulation 9.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "9. Where a natural or legal person is established in the Union as the legal", "text_raw": "9. Where a natural or legal person is established in the Union as the legal \n\nrepresentative of a sponsor not established in the European Union in \naccordance with Article 74(1) of the Clinical Trials Regulation, that \nrepresentative shall be responsible for ensuring compliance with the sponsor's \nobligations in the State, pursuant to the Clinical Trials Regulation and these \nRegulations. \n\nProvision of medicinal products, including devices, to trial participants", "text_norm": "9 natural legal person established union legal representative sponsor established european union accordance article 74(1) clinical trial regulation representative shall responsible ensuring compliance sponsor obligation state pursuant clinical trial regulation regulation provision medicinal product including device trial participant", "start_char": 14746, "end_char": 15216, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-10", "parent_doc_id": "si-2022-0040", "section_id": "reg-10", "section_label": "Regulation 10.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "10. (1) In accordance with Article 92 of the Clinical Trials Regulation, the", "text_raw": "10. (1) In accordance with Article 92 of the Clinical Trials Regulation, the \n\nsponsor of a clinical trial shall ensure that: - \n\n(a) \n\nthe investigational medicinal products and the auxiliary \nmedicinal products used in the clinical trial, and \n\n \n \n \n \n\f[40] 9 \n\n(b) \n\nany medical devices used for the administration of such \nproducts, \n\nare made available free of charge. \n\n(2) Paragraph (1) shall not apply to a non-commercial clinical trial that is \nconducted by a non-commercial sponsor, except in circumstances where the \nsponsor has obtained the products or devices referred to in paragraph (1) free \nof charge, in which case clinical trial subjects shall not bear any cost relating to \nsuch products or devices. \n\nDamage compensation", "text_norm": "10 (1) accordance article 92 clinical trial regulation sponsor clinical trial shall ensure - (a) investigational medicinal product auxiliary medicinal product used clinical trial 40 9 (b) medical device used administration product made available free charge (2) paragraph (1) shall apply non-commercial clinical trial conducted non-commercial sponsor except circumstance sponsor obtained product device referred paragraph (1) free charge case clinical trial subject shall bear cost relating product device damage compensation", "start_char": 15216, "end_char": 15961, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-11", "parent_doc_id": "si-2022-0040", "section_id": "reg-11", "section_label": "Regulation 11.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "11. A clinical trial shall not be authorised under these Regulations, or", "text_raw": "11. A clinical trial shall not be authorised under these Regulations, or \n\nconducted in the State, unless there is in place a policy of insurance or \nindemnity scheme to provide compensation for any damage suffered by a \nsubject resulting from participation in the clinical trial, which policy or scheme \nshall be appropriate to the nature and the extent of the risk. \n\nPART 4 \n\nPROTECTION OF CLINICAL TRIAL SUBJECTS AND INFORMED \n\nCONSENT", "text_norm": "11 clinical trial shall authorised regulation conducted state unless place policy insurance indemnity scheme provide compensation damage suffered subject resulting participation clinical trial policy scheme shall appropriate nature extent risk part 4 protection clinical trial subject informed consent", "start_char": 15961, "end_char": 16403, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-12", "parent_doc_id": "si-2022-0040", "section_id": "reg-12", "section_label": "Regulation 12.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "12. (1) A clinical trial shall not be conducted in the State unless the", "text_raw": "12. (1) A clinical trial shall not be conducted in the State unless the \nconditions specified in Article 28 of the Clinical Trials Regulation are met. \n\n(2) The requirements of Article 28 (1) (b) and (c), Article 31(1) (a) and (b), \n\nand Article 32(1)(a) and (b) of the Clinical Trials Regulation do not apply in \nthe case of clinical trials in emergency situations, provided that the decision to \ninclude a subject in a trial is taken at the time of the first intervention on the \nsubject, in accordance with the protocol for that clinical trial, and that the \nadditional requirements of Article 35 are met.", "text_norm": "12 (1) clinical trial shall conducted state unless condition specified article 28 clinical trial regulation met (2) requirement article 28 (1) (b) (c) article 31(1) (a) (b) article 32(1)(a) (b) clinical trial regulation apply case clinical trial emergency situation provided decision include subject trial taken time first intervention subject accordance protocol clinical trial additional requirement article 35 met", "start_char": 16403, "end_char": 17014, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-13", "parent_doc_id": "si-2022-0040", "section_id": "reg-13", "section_label": "Regulation 13.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "13. (1) The provisions of Chapter V of the Clinical Trials Regulation shall", "text_raw": "13. (1) The provisions of Chapter V of the Clinical Trials Regulation shall \n\napply to the giving and obtaining of informed consent for all clinical trials \nconducted in the State. \n\n(2) The interview required to be conducted with the subject or his or her \nlegally designated representative, in accordance with Article 29(2)(c) of the \nClinical Trials Regulation, shall be conducted by the investigator or by – \n\n(a) \n\n(b) \n\n(c) \n\na registered medical practitioner, \n\na registered dentist, or \n\na registered nurse \n\nwhose training, experience and qualifications have been assessed by the \ninvestigator and determined to be appropriate to qualify him or her to conduct \nthe interview. \n\n \n \n \n \n \n\f10 [40] \n\n(3) In addition to the informed consent given by a guardian, a minor who is \n\ncapable of forming an opinion and assessing the information given to him or \nher, shall also assent in order to participate in a clinical trial.", "text_norm": "13 (1) provision chapter v clinical trial regulation shall apply giving obtaining informed consent clinical trial conducted state (2) interview required conducted subject legally designated representative accordance article 29(2)(c) clinical trial regulation shall conducted investigator - (a) (b) (c) registered medical practitioner registered dentist registered nurse whose training experience qualification assessed investigator determined appropriate qualify conduct interview 10 40 (3) addition informed consent given guardian minor capable forming opinion assessing information given shall also assent order participate clinical trial", "start_char": 17014, "end_char": 17947, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-14", "parent_doc_id": "si-2022-0040", "section_id": "reg-14", "section_label": "Regulation 14.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "14. A clinical trial shall not be conducted in the State unless there are", "text_raw": "14. A clinical trial shall not be conducted in the State unless there are \nadequate safeguards relating to the rights of trial subjects to physical and \nmental integrity, to privacy and to the protection of the data concerning them in \naccordance with the General Data Protection Regulation, the Data Protection \nActs 1988 to 2018 and all laws of the State giving further effect to the General \nData Protection Regulation.", "text_norm": "14 clinical trial shall conducted state unless adequate safeguard relating right trial subject physical mental integrity privacy protection data concerning accordance general data protection regulation data protection act 1988 2018 law state giving effect general data protection regulation", "start_char": 17947, "end_char": 18372, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-15", "parent_doc_id": "si-2022-0040", "section_id": "reg-15", "section_label": "Regulation 15.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "15. Where a clinical trial is to be conducted exclusively in the State, an", "text_raw": "15. Where a clinical trial is to be conducted exclusively in the State, an \ninvestigator or a person specified at Regulation 13(2) may obtain informed \nconsent by the simplified means set out in Article 30(2) of the Clinical Trials \nRegulation, provided that all of the conditions set out in Article 30(3) of the \nClinical Trials Regulation are fulfilled. \n\nPART 5 \n\nARCHIVING \n\nArchiving", "text_norm": "15 clinical trial conducted exclusively state investigator person specified regulation 13(2) may obtain informed consent simplified mean set article 30(2) clinical trial regulation provided condition set article 30(3) clinical trial regulation fulfilled part 5 archiving archiving", "start_char": 18372, "end_char": 18763, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-16", "parent_doc_id": "si-2022-0040", "section_id": "reg-16", "section_label": "Regulation 16.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "16. Without prejudice to the general obligations on sponsors and", "text_raw": "16. Without prejudice to the general obligations on sponsors and \n\ninvestigators under Article 58 of the Clinical Trials Regulation in relation to \narchiving, the clinical trial master file shall be archived in a manner which \nensures that it can be made available for inspection by the Authority.", "text_norm": "16 without prejudice general obligation sponsor investigator article 58 clinical trial regulation relation archiving clinical trial master file shall archived manner ensures made available inspection authority", "start_char": 18763, "end_char": 19063, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-17", "parent_doc_id": "si-2022-0040", "section_id": "reg-17", "section_label": "Regulation 17.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "17. The medical files of trial subjects shall be retained for the maximum", "text_raw": "17. The medical files of trial subjects shall be retained for the maximum \n\nperiod of time permitted or required by the trial site. \n\nPART 6 \n\n SUPERVISION AND CONTROL", "text_norm": "17 medical file trial subject shall retained maximum period time permitted required trial site part 6 supervision control", "start_char": 19063, "end_char": 19233, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-18", "parent_doc_id": "si-2022-0040", "section_id": "reg-18", "section_label": "Regulation 18.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "18. The Authority and the National Office, in conjunction with the", "text_raw": "18. The Authority and the National Office, in conjunction with the \nnominated ethics committee, shall supervise clinical trials authorised for conduct \nin the State and may communicate with each other in regard to same. All such \ncommunications shall be confidential.", "text_norm": "18 authority national office conjunction nominated ethic committee shall supervise clinical trial authorised conduct state may communicate regard same communication shall confidential", "start_char": 19233, "end_char": 19503, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-19", "parent_doc_id": "si-2022-0040", "section_id": "reg-19", "section_label": "Regulation 19.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "19. The Authority is designated as the competent authority for inspections", "text_raw": "19. The Authority is designated as the competent authority for inspections \npursuant to Article 78 of the Clinical Trials Regulation and shall carry out the \nfunctions of the competent authority in that regard under this Regulation. \n\n \n \n \n \n \n \n \n \n \n\f[40] 11", "text_norm": "19 authority designated competent authority inspection pursuant article 78 clinical trial regulation shall carry function competent authority regard regulation 40 11", "start_char": 19503, "end_char": 19767, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-20", "parent_doc_id": "si-2022-0040", "section_id": "reg-20", "section_label": "Regulation 20.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "20. (1) Where the State is a Member State concerned and the Authority has", "text_raw": "20. (1) Where the State is a Member State concerned and the Authority has \n\njustified grounds for considering that the requirements set out in the Clinical \nTrials Regulation are no longer met, the Authority may notify the sponsor \nand/or the investigator, forthwith or from a date specified in the notice of its \nintention to: \n\n(a) \n\n(b) \n\n(c) \n\nrevoke the authorisation of a clinical trial; \n\nsuspend a clinical trial; \n\nrequire the sponsor to modify any aspect of the clinical trial. \n\n(2) Pursuant to Article 77(2) of the Clinical Trials Regulation, before the \nAuthority takes any of the measures referred to in paragraph (1), it shall, except \nwhere immediate action is required, ask the sponsor and/or the investigator for \ntheir opinion. That opinion must be delivered within a period of seven days. \n\n(3) The Authority may consult with: \n\n(i) \n\nthe National Office, and/or \n\n(ii) \n\nthe nominated ethics committee and/or \n\n(iii) \n\n other Member States concerned, \n\nwhen considering whether the requirements set out in the Clinical Trials \nRegulation are no longer met before taking any of the measures referred to in \nparagraph (1). \n\nPART 7 \n\nSAFETY REPORTING", "text_norm": "20 (1) state member state concerned authority justified ground considering requirement set clinical trial regulation longer met authority may notify sponsor investigator forthwith date specified notice intention (a) (b) (c) revoke authorisation clinical trial suspend clinical trial require sponsor modify aspect clinical trial (2) pursuant article 77(2) clinical trial regulation authority take measure referred paragraph (1) shall except immediate action required ask sponsor investigator opinion opinion must delivered within period seven day (3) authority may consult (i) national office (ii) nominated ethic committee (iii) member state concerned considering whether requirement set clinical trial regulation longer met taking measure referred paragraph (1) part 7 safety reporting", "start_char": 19767, "end_char": 20939, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-21", "parent_doc_id": "si-2022-0040", "section_id": "reg-21", "section_label": "Regulation 21.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "21. (1) The Authority may consult with the National Office in accordance", "text_raw": "21. (1) The Authority may consult with the National Office in accordance \n\nwith Article 44 (3) of the Clinical Trials Regulation.", "text_norm": "21 (1) authority may consult national office accordance article 44 (3) clinical trial regulation", "start_char": 20939, "end_char": 21071, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-22", "parent_doc_id": "si-2022-0040", "section_id": "reg-22", "section_label": "Regulation 22.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "22. The Authority may, by notifying the sponsor, require him or her to send", "text_raw": "22. The Authority may, by notifying the sponsor, require him or her to send \nthe records referred to in 41(3) of the Clinical Trials Regulation, or copies of \nsuch records, to the Authority. \n\nMANUFACTURING AND IMPORTATION OF MEDICINAL PRODUCTS \nUSED IN CLINICAL TRIALS \n\nPART 8", "text_norm": "22 authority may notifying sponsor require send record referred 41(3) clinical trial regulation copy record authority manufacturing importation medicinal product used clinical trial part 8", "start_char": 21071, "end_char": 21352, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-23", "parent_doc_id": "si-2022-0040", "section_id": "reg-23", "section_label": "Regulation 23.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "23. The provisions of Chapters IX and X of the Clinical Trials Regulation", "text_raw": "23. The provisions of Chapters IX and X of the Clinical Trials Regulation \nshall apply to the manufacturing, importation, and labelling of investigational \nmedicinal products and auxiliary medicinal products for use in clinical trials.", "text_norm": "23 provision chapter ix x clinical trial regulation shall apply manufacturing importation labelling investigational medicinal product auxiliary medicinal product use clinical trial", "start_char": 21352, "end_char": 21590, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-24", "parent_doc_id": "si-2022-0040", "section_id": "reg-24", "section_label": "Regulation 24.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "24. Commission Delegated Regulation (EU) 2017/1569 and the", "text_raw": "24. Commission Delegated Regulation (EU) 2017/1569 and the \ncomplementary detailed Commission guideline on good manufacturing \n\n \n \n \n \n \n \n \n\f12 [40] \n\npractice for investigational medicinal products, shall apply from the 31st of \nJanuary 2022, the date on which the Clinical Trials Regulation applies.", "text_norm": "24 commission delegated regulation (eu) 2017 1569 complementary detailed commission guideline good manufacturing 12 40 practice investigational medicinal product shall apply 31st january 2022 date clinical trial regulation applies", "start_char": 21590, "end_char": 21896, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-25", "parent_doc_id": "si-2022-0040", "section_id": "reg-25", "section_label": "Regulation 25.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "25. (1) The requirement under Article 61(1) of the Clinical Trials", "text_raw": "25. (1) The requirement under Article 61(1) of the Clinical Trials \n\nRegulation shall not apply to the processes specified in Article 61(5) thereof, \nwhere those processes are carried out by or under the personal supervision of a \nregistered pharmacist, a registered medical practitioner, or a registered dentist \nin hospitals, health centres or clinics, and if the investigational medicinal \nproducts are intended to be used exclusively in hospitals, health centres or \nclinics taking part in the same clinical trial in the State. \n\nPART 9 \n\nFEES", "text_norm": "25 (1) requirement article 61(1) clinical trial regulation shall apply process specified article 61(5) thereof process carried personal supervision registered pharmacist registered medical practitioner registered dentist hospital health centre clinic investigational medicinal product intended used exclusively hospital health centre clinic taking part clinical trial state part 9 fee", "start_char": 21896, "end_char": 22446, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-26", "parent_doc_id": "si-2022-0040", "section_id": "reg-26", "section_label": "Regulation 26.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "26. (1) In accordance with Article 86 of the Clinical Trials Regulation, the", "text_raw": "26. (1) In accordance with Article 86 of the Clinical Trials Regulation, the \n\nAuthority may charge fees to a sponsor for activities set out in the Clinical \nTrials Regulation. \n\n(2) The amount of the fee, or fees under paragraph (1) shall be— \n\n(a) \n\nreviewed on an annual basis by the Authority and the National \nOffice and approved by the Minister, and \n\n(b) published on the websites of the Authority and the National \n\nOffice. \n\n(3) The fees under paragraph (1) shall be— \n\n(a) payable immediately upon submission of a clinical trial \n\napplication through the EU portal in accordance with Article 5 \nand Article 14 of the Clinical Trials Regulation, \n\n(b) where applicable, payable immediately upon submission of a \nsubstantial modification through the EU portal in accordance \nwith Article 16 of the Clinical Trials Regulation, \n\n(c) \n\nnon-refundable once the clinical trial application has been \nvalidated in accordance with Article 5, Article 17 or Article 20 \nof the Clinical Trials Regulation. \n\nPART 10 \n\nAPPEALS", "text_norm": "26 (1) accordance article 86 clinical trial regulation authority may charge fee sponsor activity set clinical trial regulation (2) amount fee fee paragraph (1) shall be-- (a) reviewed annual basis authority national office approved minister (b) published website authority national office (3) fee paragraph (1) shall be-- (a) payable immediately upon submission clinical trial application eu portal accordance article 5 article 14 clinical trial regulation (b) applicable payable immediately upon submission substantial modification eu portal accordance article 16 clinical trial regulation (c) non-refundable clinical trial application validated accordance article 5 article 17 article 20 clinical trial regulation part 10 appeal", "start_char": 22446, "end_char": 23472, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-27", "parent_doc_id": "si-2022-0040", "section_id": "reg-27", "section_label": "Regulation 27.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "27. (1) A sponsor may, within 28 days of receipt of a decision, give notice", "text_raw": "27. (1) A sponsor may, within 28 days of receipt of a decision, give notice \nto the Authority of his or her wish to submit an appeal pursuant to Article 8(4), \n14(10), 19(2), 20(7), or 23(4) of the Clinical Trials Regulation. \n\n(2) The Authority shall publish guidelines setting out the procedures \n\napplicable to appeals under paragraph (1). \n\n \n \n \n \n \n \n\f[40] 13 \n\nPART 11 \n\nLANGUAGE", "text_norm": "27 (1) sponsor may within 28 day receipt decision give notice authority wish submit appeal pursuant article 8(4) 14(10) 19(2) 20(7) 23(4) clinical trial regulation (2) authority shall publish guideline setting procedure applicable appeal paragraph (1) 40 13 part 11 language", "start_char": 23472, "end_char": 23861, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-28", "parent_doc_id": "si-2022-0040", "section_id": "reg-28", "section_label": "Regulation 28.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "28. For clinical trials to be conducted in the State and for the purposes of", "text_raw": "28. For clinical trials to be conducted in the State and for the purposes of \n\nArticle 26 of the Clinical Trials Regulation, the \n\n(a) \n\napplication dossier described under Article 25 of the Clinical \nTrials Regulation, and \n\n(b) \n\nany documentation addressed to subjects, \n\nshall be in English \n\nPART 12 \n\nOFFENCES, PENALTIES, AND ENFORCEMENT \n\nOffences and penalties", "text_norm": "28 clinical trial conducted state purpose article 26 clinical trial regulation (a) application dossier described article 25 clinical trial regulation (b) documentation addressed subject shall english part 12 offence penalty enforcement offence penalty", "start_char": 23861, "end_char": 24232, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-29", "parent_doc_id": "si-2022-0040", "section_id": "reg-29", "section_label": "Regulation 29.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "29. (1) A person who -", "text_raw": "29. (1) A person who - \n\n(a) \n\ncommences a trial in the State without- \n\n(i) \n\nnotification of authorisation in accordance with Article 8 \nof the Clinical Trials Regulation, or \n\n(ii) having in place a scheme to provide compensation for any \ndamage suffered by a subject resulting from a clinical trial \nin accordance with Regulation 11, \n\n(b) \n\ncommences a substantial modification to a clinical trial without \nnotification of authorisation in accordance with Articles 19, 20, \nand 23 of the Clinical Trials Regulation, \n\n(c) \n\nconducts a clinical trial, other than in accordance with the \nrequirements of Article 47 of the Clinical Trials Regulation, \n\n(d) performs the functions of the sponsor of a clinical trial (whether \nthat person is the sponsor or is acting under arrangements made \nwith that sponsor) other than in accordance with the \nrequirements of the Clinical Trials Regulation and Regulation \n8(2), \n\n(e) \n\n(f) \n\n(g) \n\n(h) \n\nperforms the functions of the investigator of a clinical trial, other \nthan in accordance with the requirements of the Clinical Trials \nRegulation and Regulation 8(2), \n\ncharges a fee to a subject of a clinical trial other than in \naccordance with Regulation 10, \n\nfails to maintain a trial master file in accordance with the \nrequirements of Article 57 of the Clinical Trials Regulation, \n\nfails to meet their obligations in relation to archiving under \nArticle 58 of the Clinical Trials Regulation, \n\n \n \n \n \n\f14 [40] \n\n(i) \n\n(j) \n\n(k) \n\nfails to retain the medical files of subjects of clinical trials in \naccordance with Regulation 17, \n\nfails to pay a fee due under Part 9, \n\nfails to comply with the requirements for the manufacture and \nimport of investigational medicinal products and auxiliary \nmedicinal products in accordance with Part 8, \n\n(l) \n\nlabels, sells or supplies a medicinal product or auxiliary \nmedicinal product other than in accordance with Regulation 23, \n\n(m) sells or supplies an investigational medicinal product for the \n\npurposes of a clinical trial knowing or having reasonable cause \nto suspect that it was manufactured, labelled, packaged or \nimported in contravention of Regulation 23, \n\n(n) otherwise than for the purpose of performing or exercising a \nduty or power imposed or conferred by or under these \nRegulations, is in possession of an investigational medicinal \nproduct knowing or having reasonable cause to suspect that it \nwas imported in contravention of Regulation 23, \n\n(o) \n\n(p) \n\nfails to comply with a notice of suspension or termination served \nunder Regulation 20, unless same has been withdrawn or \nrevoked by the Authority, \n\nfails to comply with the requirements for notifications and \nsubmissions laid down in Article 34 and 35 of the Clinical Trials \nRegulation, \n\n(q) wilfully obstructs or interferes with the exercise of a power by \n\nan authorised officer pursuant to Regulation 34, \n\n(r) without reasonable excuse, fails to comply with any request \nmade by an authorised officer under Regulation 34, \n\n(s) \n\n(t) \n\n(u) \n\n(v) \n\n(w) \n\n(x) \n\nfails to comply with the provisions laid down in the Clinical \nTrials Regulation on the submission of information intended to \nbe made publicly available to the EU database, \n\nfails to comply with safety reporting requirements as laid down \nin Articles 41, 42 and 43 of the Clinical Trials Regulation, \n\nfails to provide records requested by the Authority in accordance \nwith Regulation 22, \n\nfails to meet the requirements of Article 54 of the Clinical Trials \nRegulation in relation to Urgent Safety measures, \n\nfails to establish a legal representative in accordance with \nArticle 74 (1) of the Clinical Trials Regulation when required, \n\nfails to meet the requirements of Part 4 of these Regulations in \nrelation to the protection of clinical trial subjects and informed \nconsent, \n\n(y) \n\nfails to meets the requirements of Regulation 14, \n\nshall be guilty of an offence. \n\n \n\f[40] 15 \n\n(2) The offences listed in paragraph (1) also apply to a legal representative \n\nof a sponsor responsible for ensuring compliance with the sponsor’s \nobligations in the State pursuant to Article 74(1) of the Clinical Trials \nRegulation. \n\n(3) \n\n(a) A person guilty of an offence under these Regulations shall be \nliable on summary conviction to a fine not exceeding €3,000 or \nto imprisonment for a term not exceeding six months or both. \n\n(b) A person guilty of an offence under these Regulations shall be \nliable on conviction on indictment to a fine not exceeding \n€300,000 or to imprisonment for a term not exceeding 5 years or \nboth. \n\n(4) Where an offence under these Regulations is committed by a body \n\ncorporate and is proved to have been so committed with the consent, \nconnivance or approval of or to have been attributable to the wilful neglect on \nthe part of any person, being a director, manager, qualified person, secretary or \nother officer of the body corporate or a person who was purporting to act in \nany such capacity, that person, as well as the body corporate shall be guilty of \nan offence and shall be liable to be proceeded against and punished as if he or \nshe was guilty of the first mentioned offence. \n\n(5) Summary proceedings for an offence under these Regulations may be \n\ninstituted from the date of the offence. \n\nSeparate contraventions", "text_norm": "29 (1) person - (a) commences trial state without- (i) notification authorisation accordance article 8 clinical trial regulation (ii) place scheme provide compensation damage suffered subject resulting clinical trial accordance regulation 11 (b) commences substantial modification clinical trial without notification authorisation accordance article 19 20 23 clinical trial regulation (c) conduct clinical trial accordance requirement article 47 clinical trial regulation (d) performs function sponsor clinical trial (whether person sponsor acting arrangement made sponsor) accordance requirement clinical trial regulation regulation 8(2) (e) (f) (g) (h) performs function investigator clinical trial accordance requirement clinical trial regulation regulation 8(2) charge fee subject clinical trial accordance regulation 10 fails maintain trial master file accordance requirement article 57 clinical trial regulation fails meet obligation relation archiving article 58 clinical trial regulation 14 40 (i) (j) (k) fails retain medical file subject clinical trial accordance regulation 17 fails pay fee due part 9 fails comply requirement manufacture import investigational medicinal product auxiliary medicinal product accordance part 8 (l) label sell supply medicinal product auxiliary medicinal product accordance regulation 23 (m) sell supply investigational medicinal product purpose clinical trial knowing reasonable cause suspect manufactured labelled packaged imported contravention regulation 23 (n) otherwise purpose performing exercising duty power imposed conferred regulation possession investigational medicinal product knowing reasonable cause suspect imported contravention regulation 23 (o) (p) fails comply notice suspension termination served regulation 20 unless withdrawn revoked authority fails comply requirement notification submission laid article 34 35 clinical trial regulation (q) wilfully obstructs interferes exercise power authorised officer pursuant regulation 34 (r) without reasonable excuse fails comply request made authorised officer regulation 34 (s) (t) (u) (v) (w) (x) fails comply provision laid clinical trial regulation submission information intended made publicly available eu database fails comply safety reporting requirement laid article 41 42 43 clinical trial regulation fails provide record requested authority accordance regulation 22 fails meet requirement article 54 clinical trial regulation relation urgent safety measure fails establish legal representative accordance article 74 (1) clinical trial regulation required fails meet requirement part 4 regulation relation protection clinical trial subject informed consent (y) fails meet requirement regulation 14 shall guilty offence 40 15 (2) offence listed paragraph (1) also apply legal representative sponsor responsible ensuring compliance sponsor obligation state pursuant article 74(1) clinical trial regulation (3) (a) person guilty offence regulation shall liable summary conviction fine exceeding eur3 000 imprisonment term exceeding six month both (b) person guilty offence regulation shall liable conviction indictment fine exceeding eur300 000 imprisonment term exceeding 5 year both (4) offence regulation committed body corporate proved committed consent connivance approval attributable wilful neglect part person director manager qualified person secretary officer body corporate person purporting act capacity person well body corporate shall guilty offence shall liable proceeded punished guilty first mentioned offence (5) summary proceeding offence regulation may instituted date offence separate contravention", "start_char": 24232, "end_char": 29538, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-30", "parent_doc_id": "si-2022-0040", "section_id": "reg-30", "section_label": "Regulation 30.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "30. For the purposes of these Regulations, every contravention of a", "text_raw": "30. For the purposes of these Regulations, every contravention of a \n\nRegulation shall be deemed a separate contravention and every contravention \nof a paragraph or a subparagraph shall also be deemed to be a separate \ncontravention and shall carry the same penalty as for a single contravention of \nany Regulation of these Regulations. \n\nInfringement notices", "text_norm": "30 purpose regulation every contravention regulation shall deemed separate contravention every contravention paragraph subparagraph shall also deemed separate contravention shall carry penalty single contravention regulation regulation infringement notice", "start_char": 29538, "end_char": 29900, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-31", "parent_doc_id": "si-2022-0040", "section_id": "reg-31", "section_label": "Regulation 31.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "31. (1) If the Authority has objective grounds for considering that any", "text_raw": "31. (1) If the Authority has objective grounds for considering that any \nperson has contravened any provision to which this Regulation applies, it may \nserve upon that person a notice in writing (in these Regulations referred to as \nan “infringement notice”) – \n\n(a) \n\ninforming him or her of the Authority’s grounds for considering \nthat the person has contravened one or more of those provisions; \n\n(b) \n\nspecifying the relevant provision of these Regulations; \n\n(c) \n\nspecifying the measures which the person must take in order to \nensure that the contravention does not continue or, as the case \nmay be, does not recur; \n\n(d) \n\nrequiring the person to take those measures, within such period \nas may be specified in the notice; \n\n \n \n \n\f16 [40] \n\n(e) warning the person that unless the requirements of subparagraph \n(d) are met, further action may be taken in respect of the \ncontravention. \n\n(2) An infringement notice may include directions as to the measures to be \n\ntaken by the person on whom the notice is served to ensure that the \ncontravention does not continue or, as the case may be, does not recur, \nincluding the different ways of securing compliance. \n\n(3) If the Authority serves an infringement notice in accordance with \nparagraph (1), it shall forthwith inform the nominated ethics committee. \n\n(4) This Regulation applies to Articles 35, 37, 41-43, and 54 of the Clinical \n\nTrials Regulation. \n\nFalse or misleading information", "text_norm": "31 (1) authority objective ground considering person contravened provision regulation applies may serve upon person notice writing (in regulation referred infringement notice ) - (a) informing authority ground considering person contravened one provision (b) specifying relevant provision regulation (c) specifying measure person must take order ensure contravention continue case may recur (d) requiring person take measure within period may specified notice 16 40 (e) warning person unless requirement subparagraph (d) met action may taken respect contravention (2) infringement notice may include direction measure taken person notice served ensure contravention continue case may recur including different way securing compliance (3) authority serf infringement notice accordance paragraph (1) shall forthwith inform nominated ethic committee (4) regulation applies article 35 37 41-43 54 clinical trial regulation false misleading information", "start_char": 29900, "end_char": 31352, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-32", "parent_doc_id": "si-2022-0040", "section_id": "reg-32", "section_label": "Regulation 32.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "32. (1) A person who in the course of-", "text_raw": "32. (1) A person who in the course of- \n\n(a) \n\nsubmitting an application for authorisation to conduct a clinical \ntrial; \n\n(b) giving notice of a substantial modification to the clinical trial; \n\n(c) \n\n(d) \n\nsubmitting an application for the grant or variation of a \nmanufacturing authorisation, \n\nsubmitting information in relation to an appeal under Part 10 of \nthese Regulations; \n\nprovides to the Authority, to a nominated ethics committee, to the National \nOffice or to the Advisory Committee for Human Medicines any relevant \ninformation which is false or misleading in a material particular, shall be guilty \nof an offence. \n\n(2) A person who – \n\n(a) \n\nis conducting a clinical trial authorised in accordance with these \nRegulations; \n\n(b) \n\nis a sponsor of such a clinical trial; or \n\n(c) while acting under arrangements made with a sponsor of such a \n\nclinical trial, performs the functions of that sponsor; \n\n(d) \n\nis engaged as a qualified person in accordance with Article 61 of \nthe Clinical Trials Regulation; \n\n(e) \n\nholds a manufacturing authorisation. \n\n(f) \n\nis on the Article 61(5) Register \n\nand who, for the purposes of these Regulations, provides to the Authority or to \na nominated ethics committee or the National Office any relevant information \nwhich is false or misleading in a material particular, shall be guilty of an \noffence. \n\n \n \n \n \n\f[40] 17 \n\nDefence of due diligence", "text_norm": "32 (1) person course of- (a) submitting application authorisation conduct clinical trial (b) giving notice substantial modification clinical trial (c) (d) submitting application grant variation manufacturing authorisation submitting information relation appeal part 10 regulation provides authority nominated ethic committee national office advisory committee human medicine relevant information false misleading material particular shall guilty offence (2) person - (a) conducting clinical trial authorised accordance regulation (b) sponsor clinical trial (c) acting arrangement made sponsor clinical trial performs function sponsor (d) engaged qualified person accordance article 61 clinical trial regulation (e) hold manufacturing authorisation (f) article 61(5) register purpose regulation provides authority nominated ethic committee national office relevant information false misleading material particular shall guilty offence 40 17 defence due diligence", "start_char": 31352, "end_char": 32758, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-33", "parent_doc_id": "si-2022-0040", "section_id": "reg-33", "section_label": "Regulation 33.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "33. In any proceedings for an offence under any of the preceding provisions", "text_raw": "33. In any proceedings for an offence under any of the preceding provisions \n\nof these Regulations, it shall be a good defence for a person charged to show \nthat he or she reasonably believed that the said provisions had been complied \nwith. \n\nEnforcement", "text_norm": "33 proceeding offence preceding provision regulation shall good defence person charged show reasonably believed said provision complied with enforcement", "start_char": 32758, "end_char": 33016, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-34", "parent_doc_id": "si-2022-0040", "section_id": "reg-34", "section_label": "Regulation 34.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "34. (1) The Chief Executive of the Authority may appoint such and so", "text_raw": "34. (1) The Chief Executive of the Authority may appoint such and so \nmany officers as he or she thinks fit to be authorised officers for the purposes \nof the enforcement of these Regulations and the Clinical Trials Regulation. \n\n(2) \n\n(a) An authorised officer shall be furnished with a warrant of his or \nher appointment and when exercising a power conferred on him \nor her under this Regulation, he or she shall, if required by a \nperson thereby affected, produce the warrant to that person for \ninspection. \n\n(b) Without prejudice to subparagraph (a), good clinical practice \ninspections may be carried out on any of the following \noccasions: \n\n(i) \n\nbefore, during or after the conduct of clinical trials; \n\n(ii) \n\nas part of the verification of applications for a \nmanufacturing or marketing authorisation; \n\n(iii) as a follow-up to the granting of authorisation; \n\n(iv) where services are provided for the support of clinical \n\ntrials. \n\n(3) Subject to paragraphs (4) and (5) an authorised officer may, for the \npurpose of ensuring that these Regulations are being complied with, carry out \nall or any of the following acts – \n\n(a) \n\n(b) \n\n(c) \n\n(d) \n\nat all reasonable times, enter (if necessary, by the use of \nreasonable force) and search a premises of any class or \ndescription, \n\ninspect any medicinal product, substance, article or product \nwhich is manufactured, processed, disposed of, stored, \ndistributed, imported, exported, labelled, packaged, sold or \nsupplied, \n\nrequire the production of, inspect and, if he or she thinks fit, take \ncopies of any book, invoice, order, record, register, or other \ndocument or of any entry in any such book, invoice, order, \nrecord, register, or other document at such premises, \n\ninspect and copy or extract information from any data source \n(including personal data) within the meaning of the General \nData Protection Regulation and the Data Protection Acts 1988 to \n2018, \n\n \n \n\f18 [40] \n\n(e) \n\n(f) \n\n(g) \n\n(h) \n\n(i) \n\n(j) \n\n(k) \n\n(l) \n\ntake (without payment) samples of any medicinal product or \nsubstance stored, or kept for supply at such premises for test, \nexamination or analysis, \n\ndetain, and if necessary seize any medicinal product, substance \nor article, \n\ntake any document which he or she has reasonable cause to \nbelieve to be a document which may be required as evidence in \nproceedings under these Regulations, \n\ninspect and take copies, or samples of, labels used, or intended \nto be used on an investigational medicinal product, \n\nrequire any person carrying on, or who has carried on, an \nactivity to which these Regulations relate, or any person \ncurrently or previously employed in connection with such an \nactivity, to give to the authorised officer such information as the \nauthorised officer may reasonably require for the purposes of \nthese Regulations, \n\ntake photographs of premises and equipment, \n\ncontact the subject of a clinical trial directly, in accordance with \nArticle 10(6) of Regulation (EU) 2017/556, and \n\nask any representative or member of staff of the inspected entity \nand any party involved in the clinical trial for explanations \nrelating to the subject matter and purpose of the inspection and \nrecord the answer. \n\n(4) An authorised officer shall not, other than with the consent of the \n\noccupier, enter a private dwelling unless he or she has obtained a warrant from \nthe District Court under paragraph (10) authorising such entry. \n\n(5) Any expert who accompanies an authorised officer may: \n\n(a) \n\n(b) \n\nask any representative or member of staff of the inspected entity \nand any party involved in the clinical trial for explanations \nrelating to the subject matter and purpose of the inspection and \nrecord the answer, \n\nreview, record, and extract information from any data (including \npersonal data) within the meaning of the General Data \nProtection Regulation and the Data Protection Acts 1988 to", "text_norm": "34 (1) chief executive authority may appoint many officer think fit authorised officer purpose enforcement regulation clinical trial regulation (2) (a) authorised officer shall furnished warrant appointment exercising power conferred regulation shall required person thereby affected produce warrant person inspection (b) without prejudice subparagraph (a) good clinical practice inspection may carried following occasion (i) conduct clinical trial (ii) part verification application manufacturing marketing authorisation (iii) follow-up granting authorisation (iv) service provided support clinical trial (3) subject paragraph (4) (5) authorised officer may purpose ensuring regulation complied carry following act - (a) (b) (c) (d) reasonable time enter (if necessary use reasonable force) search premise class description inspect medicinal product substance article product manufactured processed disposed stored distributed imported exported labelled packaged sold supplied require production inspect think fit take copy book invoice order record register document entry book invoice order record register document premise inspect copy extract information data source (including personal data) within meaning general data protection regulation data protection act 1988 2018 18 40 (e) (f) (g) (h) (i) (j) (k) (l) take (without payment) sample medicinal product substance stored kept supply premise test examination analysis detain necessary seize medicinal product substance article take document reasonable cause believe document may required evidence proceeding regulation inspect take copy sample label used intended used investigational medicinal product require person carrying carried activity regulation relate person currently previously employed connection activity give authorised officer information authorised officer may reasonably require purpose regulation take photograph premise equipment contact subject clinical trial directly accordance article 10(6) regulation (eu) 2017 556 ask representative member staff inspected entity party involved clinical trial explanation relating subject matter purpose inspection record answer (4) authorised officer shall consent occupier enter private dwelling unless obtained warrant district court paragraph (10) authorising entry (5) expert accompanies authorised officer may (a) (b) ask representative member staff inspected entity party involved clinical trial explanation relating subject matter purpose inspection record answer review record extract information data (including personal data) within meaning general data protection regulation data protection act 1988", "start_char": 33016, "end_char": 36927, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-2018", "parent_doc_id": "si-2022-0040", "section_id": "reg-2018", "section_label": "Regulation 2018.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "(6) When exercising a power under this Regulation, an authorised officer", "text_raw": "2018. \n\n(6) When exercising a power under this Regulation, an authorised officer \n\nmay, subject to any warrant under paragraph (10), be accompanied by such \nnumber of: \n\n(a) other authorised officers, \n\n(b) \n\ninspectors from the competent authority of another Member \nState, or \n\n(c) \n\npersons with expertise relevant to the aspects being examined, \n\n \n\f[40] 19 \n\n(d) members of An Garda Síochána or Customs and Excise \n\nOfficers, \n\nas he or she considers appropriate in the circumstances of the case. \n\n(7) The Authority shall ensure that confidentiality is respected by \n\nauthorised officers and other experts engaged in inspections and, with regard to \npersonal data, that the requirements of the General Data Protection Regulation \nand Data Protection Acts 1988 to 2018 are respected. \n\n(8) An authorised officer, for the purpose of exercising any of the powers \nconferred on him or her by paragraph (3), may require any other person, having \nauthority to do so, to break open any container or package or to permit him or \nher to do so. \n\n(9) Where an authorised officer detains or seizes any medicinal product, \nsubstance, article or document in the exercise of a power conferred on him or \nher by paragraph (3), he or she shall inform the person from whom it is \ndetained or seized. \n\n(10) If a judge of the District Court is satisfied, on the sworn information of \nan authorised officer, that there are reasonable grounds to authorise entry into \nany premises referred to in paragraph (4), the judge may issue a warrant \nauthorising such an authorised officer, accompanied, if appropriate, by other \nauthorised officers or by a member or members of the Garda Síochána, or both, \nat any time or times within one month from the date of issue of the warrant, on \nproduction of the warrant if requested, to enter those premises or part thereof \nand to exercise any of the powers conferred on such an authorised officer under \nthis Regulation. \n\n(11) A person shall not wilfully obstruct or interfere with the exercise of a \n\npower by an authorised officer pursuant to this Regulation. \n\n(12) A person shall not, without reasonable excuse, fail to comply with any \n\nrequest made by an authorised officer under this Regulation. \n\n(13) Any material taken away by an authorised officer under this Regulation \n\nmay be retained by him or her for use as evidence in any proceedings. \n\nProsecution of offences", "text_norm": "2018 (6) exercising power regulation authorised officer may subject warrant paragraph (10) accompanied number (a) authorised officer (b) inspector competent authority another member state (c) person expertise relevant aspect examined 40 19 (d) member garda siochana custom excise officer considers appropriate circumstance case (7) authority shall ensure confidentiality respected authorised officer expert engaged inspection regard personal data requirement general data protection regulation data protection act 1988 2018 respected (8) authorised officer purpose exercising power conferred paragraph (3) may require person authority break open container package permit so (9) authorised officer detains seizes medicinal product substance article document exercise power conferred paragraph (3) shall inform person detained seized (10) judge district court satisfied sworn information authorised officer reasonable ground authorise entry premise referred paragraph (4) judge may issue warrant authorising authorised officer accompanied appropriate authorised officer member member garda siochana time time within one month date issue warrant production warrant requested enter premise part thereof exercise power conferred authorised officer regulation (11) person shall wilfully obstruct interfere exercise power authorised officer pursuant regulation (12) person shall without reasonable excuse fail comply request made authorised officer regulation (13) material taken away authorised officer regulation may retained use evidence proceeding prosecution offence", "start_char": 36927, "end_char": 39334, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-35", "parent_doc_id": "si-2022-0040", "section_id": "reg-35", "section_label": "Regulation 35.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "35. Proceedings in relation to a summary offence under these Regulations", "text_raw": "35. Proceedings in relation to a summary offence under these Regulations \n\nmay be brought and prosecuted by the Authority. \n\nPART 13 \n\nJOINT CONTROLLERSHIP ARRANGEMENT", "text_norm": "35 proceeding relation summary offence regulation may brought prosecuted authority part 13 joint controllership arrangement", "start_char": 39334, "end_char": 39504, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-36", "parent_doc_id": "si-2022-0040", "section_id": "reg-36", "section_label": "Regulation 36.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "36. For the purposes of the Joint Controllership Arrangement, the Authority", "text_raw": "36. For the purposes of the Joint Controllership Arrangement, the Authority \n\nand the National Office shall be the State’s joint controllers in relation to the \nprocessing of personal data captured in the EU portal. \n\n \n \n \n \n \n\f20 [40] \n\nRevocations \n\nPART 14 \n\nREVOCATIONS", "text_norm": "36 purpose joint controllership arrangement authority national office shall state joint controller relation processing personal data captured eu portal 20 40 revocation part 14 revocation", "start_char": 39504, "end_char": 39781, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-37", "parent_doc_id": "si-2022-0040", "section_id": "reg-37", "section_label": "Regulation 37.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "37. Subject to Regulation 39, the following are revoked:", "text_raw": "37. Subject to Regulation 39, the following are revoked: \n\n(a) European Communities (Clinical Trials on Medicinal Products \nfor Human Use) Regulations 2004 (S.I. No. 190 of 2004); \n\n(b) European Communities (Clinical Trials on Medicinal Products \nfor Human Use) (Amendment) Regulations 2004 (S.I. No. 878 \nof 2004); \n\n(c) European Communities (Clinical Trials on Medicinal Products \n\nfor Human Use) (Amendment No. 2) Regulations 2006 (S.I. No. \n374 of 2006); \n\n(d) European Communities (Clinical Trials on Medicinal Products \nfor Human Use) (Amendment) Regulations 2009 (S.I. No. 1 of \n2009). \n\nENTRY INTO FORCE AND TRANSITIONAL ARRANGEMENTS \n\nPART 15", "text_norm": "37 subject regulation 39 following revoked (a) european community (clinical trial medicinal product human use) regulation 2004 (s.i no 190 2004) (b) european community (clinical trial medicinal product human use) (amendment) regulation 2004 (s.i no 878 2004) (c) european community (clinical trial medicinal product human use) (amendment no 2) regulation 2006 (s.i no 374 2006) (d) european community (clinical trial medicinal product human use) (amendment) regulation 2009 (s.i no 1 2009) entry force transitional arrangement part 15", "start_char": 39781, "end_char": 40435, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-38", "parent_doc_id": "si-2022-0040", "section_id": "reg-38", "section_label": "Regulation 38.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "38. (1) These Regulations will come into operation on the 31st day of", "text_raw": "38. (1) These Regulations will come into operation on the 31st day of \nJanuary 2022 and shall only apply to clinical trial applications submitted under \nthe Clinical Trials Regulation. \n\nTransitional arrangements", "text_norm": "38 (1) regulation come operation 31st day january 2022 shall apply clinical trial application submitted clinical trial regulation transitional arrangement", "start_char": 40435, "end_char": 40650, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-reg-39", "parent_doc_id": "si-2022-0040", "section_id": "reg-39", "section_label": "Regulation 39.", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "39. Notwithstanding the revocation, by Regulation 37, of the European", "text_raw": "39. Notwithstanding the revocation, by Regulation 37, of the European \n\nCommunities (Clinical Trials on Medicinal Products for Human Use) \nRegulations 2004 (S.I. 190 of 2004) - \n\n(a) \n\nthose Regulations shall continue to apply until the 30th day of \nJanuary 2025 \n\n(i) \n\n(ii) \n\nin respect of an application submitted in accordance with \nthose Regulations before the 31st day of January 2022, and \nin respect of an application made on or before the 31st day \nof January 2023, where the sponsor opted to make the \napplication in accordance with those Regulations, and \n\n(b) \n\na sponsor of a clinical trial that received a favourable opinion \nfrom an ethics committee recognised by the Minister in \naccordance with Part 2 of those Regulations and, in relation to \nwhich trial the Authority granted an authorisation, shall continue \nto comply with his or her reporting obligations under those \nRegulations until the 31st day of January 2025. \n\n \n \n \n \n \n\f[40] 21 \n\nGIVEN under the Official Seal of the Minister for Health, \n\n31 January, 2022. \n\nMUIRIS O’CONNOR, \n\nA person authorised under section 15 of the Ministers and \nSecretaries Act 1924 to authenticate the seal of the Minister \nfor Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f22 [40]", "text_norm": "39 notwithstanding revocation regulation 37 european community (clinical trial medicinal product human use) regulation 2004 (s.i 190 2004) - (a) regulation shall continue apply 30th day january 2025 (i) (ii) respect application submitted accordance regulation 31st day january 2022 respect application made 31st day january 2023 sponsor opted make application accordance regulation (b) sponsor clinical trial received favourable opinion ethic committee recognised minister accordance part 2 regulation relation trial authority granted authorisation shall continue comply reporting obligation regulation 31st day january 2025 40 21 given official seal minister health 31 january 2022 muiris connor person authorised section 15 minister secretary act 1924 authenticate seal minister health 22 40", "start_char": 40650, "end_char": 41883, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
{"doc_id": "si-2022-0040-explanatory-note", "parent_doc_id": "si-2022-0040", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 40 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation). \n\nThese Regulations give further effect to Regulation (EC) No. 536/2014 of \nthe European Parliament and of the Council of 16 April 2014 on clinical \ntrials on medicinal products for human use (“Clinical Trials Regulation”) \nwhich applied from the 31st of January 2022. \n\nThe Clinical Trials Regulation replaces and repeals Directive 2001/20/EC on \nthe approximation of the laws, regulations and administrative provisions of \nthe Member States relating to the implementation of good clinical practice \nin the conduct of clinical trials on medicinal products for human use. \n\nThe Regulations provide that the Health Products Regulatory Authority will \nexercise the functions of the competent “Authority” for the purposes of the \nClinical Trials Regulation and for the purposes of supervision and \nenforcement as required by the Regulations. \n\nThe National Office and National Research Ethics Committees, as provided \nfor in the Clinical Trials Regulation, have been defined in separate \nRegulations, the European Union Clinical Trials on Medicinal Products for \nHuman Use) (National Research Ethics Committees) Regulations 2022 (S.I. \nNo. 41 of 2022). \n\n \n \n \n \n \n \n \n \n\f[40] 23 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€6.50 \n\n(DH-378) 75. 2/22. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation) regulation give effect regulation (ec) no 536 2014 european parliament council 16 april 2014 clinical trial medicinal product human use ( clinical trial regulation ) applied 31st january 2022 clinical trial regulation replaces repeal directive 2001 20 ec approximation law regulation administrative provision member state relating implementation good clinical practice conduct clinical trial medicinal product human use regulation provide health product regulatory authority exercise function competent authority purpose clinical trial regulation purpose supervision enforcement required regulation national office national research ethic committee provided clinical trial regulation defined separate regulation european union clinical trial medicinal product human use) (national research ethic committees) regulation 2022 (s.i no 41 2022) 40 23 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur6.50 (dh-378) 75 2 22 propylon", "start_char": 41883, "end_char": 43657, "source_path": "downloads\\2022\\2022_0039.pdf", "extraction_method": "pdfminer", "checksum": "sha256:d8a96907617d3abb899d2725b68bff097d6f954881e991da1dc188b7370a3d6c", "cross_refs": []}
